Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2005

View Archived Issues

Sangamo and Pfizer enter enhanced protein production research collaboration

Chugai licenses Xencor's XmAb technology for optimized antibodies

North American lung transplant program under way for ATG-Fresenius S

Altachem receives Canadian governmental support for prostate cancer therapy

Sirna and Targeted Genetics form Huntington's disease collaboration

Sepracor and Acadia announce CNS R&D collaboration

Phase II planned for PTH (1-34) after merger

Locus enters into CRADA with NCI to develop new cancer treatments

MEM-1003 enters U.S. safety and tolerability study for Alzheimer's

Xoma restructures Raptiva agreement with Genentech

Approvable letter for Biovail's orally disintegrating tramadol

Yasmin receives Canadian approval

Bristol-Myers Squibb and Medarex begin MDX-010 collaboration

AstraZeneca withdraws European MAA for Iressa in NSCLC

HSV-TK gene therapy program to enter phase III this year

Avastin receives E.U. approval

Long-term vitamin E supplementation reported to reduce mortality due to ALS

Novel CRTH2 receptor antagonists prepared and tested at Bayer

Evidence suggests that retinitis pigmentosa may be caused by mutations in the CA4 gene

New HIV integrase inhibitors developed by Tibotec-Virco

Raloxifene reported to reduce incidence of breast cancer in postmenopausal women

AstraZeneca patent claims new treatments for cancer

Novartis discloses sphingosine-1-phosphate receptor modulators

Incyte describes metalloprotease inhibitors for arthritis and other uses

KCNQ2 channel activators for epilepsy, neuropathic pain, etc.

ETC-216 is cardioprotective in a rabbit model of ischemia-reperfusion

PARP inhibitor reduces brain infarct size in rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...